Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 21;23(9):4577.
doi: 10.3390/ijms23094577.

Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review

Affiliations

Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review

Carlos Aranaga et al. Int J Mol Sci. .

Abstract

Bacteriophages offer an alternative for the treatment of multidrug-resistant bacterial diseases as their mechanism of action differs from that of antibiotics. However, their application in the clinical field is limited to specific cases of patients with few or no other alternative therapies. This systematic review assesses the effectiveness and safety of phage therapy against multidrug-resistant bacteria through the evaluation of studies published over the past decade. To that end, a bibliographic search was carried out in the PubMed, Science Direct, and Google Scholar databases. Of the 1500 studies found, 27 met the inclusion criteria, with a total of 165 treated patients. Treatment effectiveness, defined as the reduction in or elimination of the bacterial load, was 85%. Except for two patients who died from causes unrelated to phage therapy, no serious adverse events were reported. This shows that phage therapy could be an alternative treatment for patients with infections associated with multidrug-resistant bacteria. However, owing to the phage specificity required for the treatment of various bacterial strains, this therapy must be personalized in terms of bacteriophage type, route of administration, and dosage.

Keywords: bacteriophages; infections; multidrug-resistant bacteria; phage therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart illustrating the search and selection of the articles.
Figure 2
Figure 2
Number of infections caused by each of the multidrug-resistant bacteria mentioned in the articles.

References

    1. Pires D.P., Cleto S., Sillankorva S., Azeredo J., Lu T.K. Genetically Engineered Phages: A Review of Advances over the Last Decade. Microbiol. Mol. Biol. Rev. 2016;80:523–543. doi: 10.1128/MMBR.00069-15. - DOI - PMC - PubMed
    1. Payaslian F., Gradaschi V., Piuri M. Genetic Manipulation of Phages for Therapy Using BRED. Curr. Opin. Biotechnol. 2021;68:8–14. doi: 10.1016/j.copbio.2020.09.005. - DOI - PubMed
    1. Henry M., O’Sullivan O., Sleator R.D., Coffey A., Ross R.P., McAuliffe O., O’Mahony J.M. In Silico Analysis of Ardmore, a Novel Mycobacteriophage Isolated from Soil. Gene. 2010;453:9–23. doi: 10.1016/j.gene.2009.12.007. - DOI - PubMed
    1. Kilcher S., Loessner M.J. Engineering Bacteriophages as Versatile Biologics. Trends Microbiol. 2019;27:355–367. doi: 10.1016/j.tim.2018.09.006. - DOI - PubMed
    1. Pérez-Martínez D.A., Puente-Muñoz A.I. Bacterias, Endotoxinas Y Neuroinflamación Crónica: ¿Una Etiopatogenia Para Las Enfermedad De Alzheimer? Rev. Ecuatoriana Neurol. 2020;29:137–144. doi: 10.46997/revecuatneurol29100137. - DOI

Publication types

Substances